Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Neoplasma Vol.67, No.4, p.715–723, 2020 |
||
Title: Adverse events and management of apatinib in patients with advanced or metastatic cancers: A review | ||
Author: F. Shao, H. Zhang, X. Yang, X. Luo, J. Liu | ||
Abstract: Apatinib (YN968D1) is a novel and highly selective tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor-2 (VEGFR-2) and is approved as a third-line and subsequent-line treatment for advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma in China. Apatinib is also widely studied in other solid tumors. With the increase in clinical research of apatinib, its adverse effects have also received widespread attention. Hence, this article summarizes the pharmacological properties of apatinib and reviews its clinical use in advanced or metastatic cancers. We highlight the common adverse reactions of apatinib in clinical applications and we also clarify the corresponding prevention and intervention measures. Overall, this review will help us better understand the safety and efficacy of apatinib treatment. |
||
Keywords: apatinib, VEGFR, adverse effects, malignant cancer, antiangiogenic targeted therapy | ||
Published online: 07-Apr-2020 | ||
Year: 2020, Volume: 67, Issue: 4 | Page From: 715, Page To: 723 | |
doi:10.4149/neo_2020_190801N701 |
||
|
download file |
|